{
    "clinical_study": {
        "@rank": "142754", 
        "biospec_descr": {
            "textblock": "A total of 6 teaspoons of blood will be drawn."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Donor-Specific Antibody (DSA) (HLA) levels and non-HLA antibody levels in recipients prior\n      to living kidney transplantation and randomize these individuals into a desensitization\n      protocol in order to evaluate shifts that can occur with the Luminex and XM-One assay after\n      treatment and up to 6 months post transplant.\n\n      If desensitization is needed prior to transplantation in individuals with a negative\n      crossmatch but positive DSA and/or XM-one - patients will be evaluated clinically with\n      routine lab tests (serum creatinine levels, spot urine protein and spot urine creatinine\n      levels) as well as protocol biopsy evaluations."
        }, 
        "brief_title": "XM-One Study for Living Donor Program", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Transplant; Failure, Kidney", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "1. Rates of acute rejection including subclinical rejection - acute T cell mediated\n           (cellular) rejection, antibody mediated acute rejection, and chronic\n           antibody-associated injury (i.e.: Transplant Glomerulopathy, Chronic allograft\n           arteriopathy) between the groups.\n\n        2. Evaluation of endothelial cell activation and injury on biopsies by checking markers\n           for endothelial cell activation and injury (intercellular adhesion molecule-1,\n           ICAM-1/CD54; vascular cell adhesion molecule-1, VCAM-1/CD106; and E-selectin,\n           ELAM-1/CD62E) in two-color stains of tissue with classical endothelial markers (CD34\n           and Factor VIII).\n\n        3. Measurement of serum/plasma levels of TNF-alpha and VEGF and decreased levels of\n           protein C and protein S in the circulation, as an assessment of graft vascular\n           perturbation.\n\n        4. Circulating Endothelial Cells (CECs) will be measured by flow cytometry with markers\n           for endothelial cell activation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recipients receiving deceased donor transplants.\n\n          -  Living donor transplant that is T-cell flow crossmatch positive.\n\n          -  HIV, Hepatitis C and B positive patients.\n\n        Exclusion Criteria:\n\n          -  Pregnant women and children will be excluded from the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Living donor kidney transplant recipients"
            }
        }, 
        "enrollment": {
            "#text": "138", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679184", 
            "org_study_id": "XM-One"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 22, 2013", 
        "location": {
            "contact": {
                "email": "lhanson2@med.miami.edu", 
                "last_name": "Lois Hanson, R.N.", 
                "phone": "305-355-5315"
            }, 
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33186"
                }, 
                "name": "University of Miami"
            }, 
            "investigator": {
                "last_name": "Giselle Guerra, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "XM-One Study for Living Donor Program", 
        "overall_official": {
            "affiliation": "University of Miami", 
            "last_name": "Giselle Guerra, R.N.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate Donor-Specific Antibody (DSA) (HLA) levels with Luminex testing and non-HLA antibody levels using XM-One assay in recipients before and after transplantation for up to 6 months as well as in those recipients undergoing desensitization treatment.", 
            "measure": "DSA", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679184"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Miami", 
            "investigator_full_name": "Giselle Guerra", 
            "investigator_title": "Assistant Professor of Clinical", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Rates of acute rejection including subclinical rejection - acute T cell mediated (cellular) rejection, antibody mediated acute rejection, and chronic antibody-associated injury (i.e.: Transplant Glomerulopathy, Chronic allograft arteriopathy) between the groups.\nDetermine role of desensitization prior to transplantation in individuals with a negative crossmatch but positive DSA and/or XM-one - based on Luminex and XM-One testing.  Patients will be evaluated clinically with routine lab tests (serum creatinine levels, spot urine protein and spot urine creatinine levels) as well as protocol biopsy evaluations.", 
            "measure": "DSA", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "University of Miami", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Miami", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}